Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Dextroamphetamine extended-release ...

The following is a summary of “Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine,” published in the March 2025 issue of Journal of ...

Humulin R (insulin human) is a prescription drug that’s used to help manage high blood sugar levels caused by diabetes. Humulin R is given as an injection under the skin. Doctors prescribe Humulin R ...

As supply runs out for Levemir, people with diabetes have several alternatives to consider like switching to another long-acting insulin or adopting an insulin pump. Levemir, a popular long-acting ...

UBUHOLI obusha beChelsea obuholwa nguTodd Boehly buzogubha izinsuku ezingu-100 buthathe iqembu, buthungathi umqeqeshi omusha emuva kokukhomba indlela oqale nalo isizini, uThomas Tuchel ngemuva ...

"Episodes of hypoglycaemia can be dangerous for people with diabetes and can often be a significant barrier to achieving glycaemic control," said Mads Krogsgaard Thomsen, executive vice president and ...

New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba ® (insulin degludec injection U-100) resulted in significantly lower rates of overall, ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.

Tresiba ® is not recommended for the treatment of diabetic ketoacidosis and it is not known if Tresiba ® is safe and effective in children under 18 years of age. "When developing new therapies, Novo ...

In March 2013, Novo Nordisk launched Tresiba (insulin degludec), its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be priced roughly 70% higher than ...